{"id":751034,"date":"2023-04-25T16:42:43","date_gmt":"2023-04-25T20:42:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"modified":"2023-04-25T16:42:43","modified_gmt":"2023-04-25T20:42:43","slug":"foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/","title":{"rendered":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Foghorn\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is\u00a0taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae<\/sup> platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n

\n Fireside chat date and time: <\/strong>Tuesday, May 2, 2023, 1:30 p.m. ET<\/p>\n

Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the panel here<\/a>.<\/p>\n

A webcast of the panel can also be accessed under \u201cEvents & Presentations\u201d in the Investors section of Foghorn\u2019s website, www.foghorntx.com<\/a>, and will be available for up to 30 days.<\/p>\n

\n About\u00a0Foghorn\u00a0Therapeutics<\/strong>
\n
Foghorn\u00ae<\/sup>\u00a0Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control\u00ae<\/sup>\u00a0platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. Foghorn is developing multiple product candidates in oncology. For more information about Foghorn, visit our website at www.foghorntx.com<\/a>, and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com<\/a><\/p>\n

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com<\/a><\/p>\n

Michael Lampe, ScientPR (Media)
michael@scientpr.com<\/a>\u00a0<\/p>\n

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is\u00a0taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Fireside chat date and time: Tuesday, May 2, 2023, 1:30 p.m. ET Foghorn Presenter: Adrian Gottschalk, President and Chief Executive OfficerPlease find a link to the panel here. A webcast … <\/p>\n

Continue reading “Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751034","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFoghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is\u00a0taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Fireside chat date and time: Tuesday, May 2, 2023, 1:30 p.m. ET Foghorn Presenter: Adrian Gottschalk, President and Chief Executive OfficerPlease find a link to the panel here. A webcast … Continue reading "Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T20:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference\",\"datePublished\":\"2023-04-25T20:42:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"name\":\"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=\",\"datePublished\":\"2023-04-25T20:42:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is\u00a0taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Fireside chat date and time: Tuesday, May 2, 2023, 1:30 p.m. ET Foghorn Presenter: Adrian Gottschalk, President and Chief Executive OfficerPlease find a link to the panel here. A webcast … Continue reading \"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T20:42:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference","datePublished":"2023-04-25T20:42:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/","name":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=","datePublished":"2023-04-25T20:42:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTA4NyM1NTU1OTkwIzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751034"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751034\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}